Benzinga · Jul 24, 2026
Virax Biolabs Files Prospectus For Offering 1.682M Ordinary Shares
https://www.sec.gov/Archives/edgar/data/1885827/000119312526316130/vrax-20260724.htm
VR
NASDAQ · VRAX
Virax Biolabs Group Limited
Healthcare · Biotechnology
$2.82
Up+$0.04 (+1.44%)
Updated Aug 14, 2026, 12:55 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.92M
- P/E ratio
- -0.37
- Dividend yield
- 0.00%
- 52-week range
- $0.10 – $13.19
- Volume
- 31.46K
- Avg. volume
- 5.08M
Price performance
VRAX price history
1M range · 21 trading sessions · Daily adjusted prices
VRAX closed at $2.82 after 21 trading sessions, down 27.69% for the selected period.
- Last close
- $2.82
- Period change
- -27.69%
- Period low
- $2.62
- Period high
- $3.90
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $2.76 | $2.89 | $2.71 | $2.82 | 31.46K |
| Aug 12, 2026 | $2.89 | $2.89 | $2.76 | $2.78 | 38.32K |
| Aug 11, 2026 | $2.8302 | $2.91 | $2.83 | $2.87 | 20.54K |
| Aug 10, 2026 | $2.99 | $2.99 | $2.79 | $2.88 | 35.7K |
| Aug 7, 2026 | $2.81 | $2.9814 | $2.71 | $2.98 | 65.16K |
| Aug 6, 2026 | $2.76 | $2.9067 | $2.74 | $2.77 | 79.57K |
| Aug 5, 2026 | $3.10 | $3.10 | $2.84 | $2.91 | 49K |
| Aug 4, 2026 | $2.84 | $3.07 | $2.84 | $2.98 | 141.04K |
| Aug 3, 2026 | $2.62 | $2.94 | $2.5511 | $2.94 | 527.62K |
| Jul 31, 2026 | $2.78 | $2.842 | $2.58 | $2.62 | 65.4K |
| Jul 30, 2026 | $2.95 | $2.95 | $2.7501 | $2.80 | 43.45K |
| Jul 29, 2026 | $2.91 | $3.04 | $2.88 | $2.93 | 34.09K |
| Jul 28, 2026 | $3.04 | $3.0562 | $2.81 | $2.89 | 72.81K |
| Jul 27, 2026 | $3.18 | $3.288 | $3.00 | $3.10 | 53.99K |
| Jul 24, 2026 | $3.17 | $3.19 | $3.11 | $3.19 | 86.39K |
| Jul 23, 2026 | $3.53 | $3.55 | $3.11 | $3.19 | 183.59K |
| Jul 22, 2026 | $3.75 | $3.84 | $3.64 | $3.64 | 119.52K |
| Jul 21, 2026 | $3.85 | $3.95 | $3.7318 | $3.88 | 77.71K |
| Jul 20, 2026 | $3.71 | $4.11 | $3.60 | $3.89 | 315.05K |
| Jul 17, 2026 | $3.66 | $3.89 | $3.52 | $3.79 | 406.42K |
| Jul 16, 2026 | $3.66 | $4.12 | $3.46 | $3.90 | 12.55M |
Latest VRAX news
The latest Smart Investors Daily articles mentioning VRAX.
Stock researchCompany · Overview
VRAX research
Overview
Company profile and research snapshot.
Company profile
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 16, 2026
Virax Biolabs Management Believes Current Valuation Doesn't Fully Reflect Its Audited Financial Position, Clinical And Development Programs, Commercial Progress Or Strategic Assets
Dear Fellow Shareholders,Following several significant developments in recent weeks, I wanted to provide shareholders with a concise update on Virax's current position and priorities.Our fiscal 2026 Annual Report
Benzinga · Jul 10, 2026
Dow Gains 50 Points; Simulations Plus Earnings Top Views
Dow Jones up 0.1% on Friday with NASDAQ and S&P 500 also rising. Communication services shares jumped 0.9% while health care fell 0.5%. Simulations Plus Inc beats earnings estimates, WD-40 Co and Jiuzi Holdings Inc see gains, eLong Power Holding Ltd and Virax Biolabs Group Ltd see losses. European shares mixed, Asian markets close mixed.
Benzinga · Jul 10, 2026
US Stocks Edge Higher; Delta Air Lines Posts Upbeat Q2 Earnings
Dow Jones up 0.1%, Nasdaq up 0.07%, S&P 500 up 0.11%. Communication services up 0.9% and Health care down 0.8%. Delta Air Lines beats earnings.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
